Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Pipeline Review, H2 2016

  • ID: 3939702
  • Drug Pipelines
  • 32 pages
  • Global Markets Direct
1 of 6
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Pipeline Review, H2 2016

Summary

‘Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Pipeline Review, H2 2016’, provides in depth analysis on Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2)
- The report reviews Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) Overview

Therapeutics Development

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Products under Development by Stage of Development

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Products under Development by Therapy Area

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Products under Development by Indication

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Products under Development by Companies

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Companies Involved in Therapeutics Development

A. Menarini Industrie Farmaceutiche Riunite Srl

Albireo AB

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Drug Profiles

A-3914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-5425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTI-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibodutant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nepadutant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NK 1 and NK 2 Receptors for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Dormant Projects

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016

Pipeline by Albireo AB, H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Discontinued Products, H2 2016 30List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.Our latest report Substance K Receptor – Pipeline Review, H2 2016, outlays comprehensive information on the Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) Substance K receptor is a G-protein coupled receptor expressed predominantly in the CNS. Networks involved in emotional processing, such as the prefrontal cortex, cingulate cortex, and amygdala, show the highest concentration of NK-2 receptors.NK-2 receptor antagonists have antidepressant benefits. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively.

Furthermore, this report also reviews key players involved in Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
A. Menarini Industrie Farmaceutiche Riunite Srl
Albireo AB
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll